RCS - Fusion Antibodies - OptiMAL Library video

Fusion AntibodiesAnnouncement

13/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251113:nRSM3019Ha&default-theme=true

RNS Number : 3019H  Fusion Antibodies PLC  13 November 2025

REACH - Non-regulatory announcement*

 

13 November 2025

Fusion Antibodies plc

("Fusion" or the "Company")

 

OptiMAL Library video

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, has prepared a short video of Dr Richard Buick, CSO, explaining
some of the features, science and technology behind the Company's Opti-library
of antibody sequences.

 

The Opti-library design and method is protected by US patent no. 17/287,441.
It has been combined with Fusion's mammalian display platform to create the
OptiMAL(®) library, and it intended to be used to discover novel human
antibodies against any target. OptiMAL(®) is due for commercial launch in
December 2025.

 

The video can be viewed on the Investor Hub section of Fusion's website at,
https://investorhub.fusionantibodies.com/s/7ea305
(https://investorhub.fusionantibodies.com/s/7ea305) .

 

This video is the latest in a series of videos providing shareholders and
investors with more information on the Company's technological platforms and
service offerings. These videos can be found here
https://investorhub.fusionantibodies.com/s/1b6535
(https://investorhub.fusionantibodies.com/s/1b6535) .

 

Enquiries:

 

 Investor questions on this announcement
 We encourage all investors to share questions on this announcement via our      Investor hub (https://investorhub.fusionantibodies.com/)
 investor hub

 Fusion Antibodies plc                                                           www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                                         Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                                         Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                                      Tel: +44 (0) 207 186 9952

 Walbrook PR                             Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                     Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

*About Reach announcements

This is a Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain.  Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPGBPGUPAGQP



            Copyright 2019 Regulatory News Service, all rights reserved